Madrigal Pharmaceuticals, Inc. MDGL Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $1.13B+18.2% | $958.4M+29.4% | $740.64M+43.7% | $515.55M+62.4% | $317.38M+76.2% | ||
| —— | —— | —— | —— | —— | ||
| $453.05M+16.6% | $388.53M+30.4% | $297.91M+54.6% | $192.64M-8.1% | $209.65M-11.4% | ||
| $914.47M+12.4% | $813.83M+13.8% | $715.07M+16.5% | $613.54M+17.5% | $522.13M+20.0% | ||
| $1.45B+14.9% | $1.26B+20.1% | $1.05B+27.0% | $825.36M+11.2% | $742.53M+9.5% | ||
| $1.45B+14.9% | $1.26B+20.1% | $1.05B+27.0% | $825.36M+11.2% | $742.53M+9.5% | ||
| $78.48M+39.8% | $56.15M-92.1% | $706.92M+2.3% | $690.95M+1.2% | $682.52M+0.7% | ||
| -$313.51M-4.5% | -$300.1M+2.4% | -$307.48M+0.8% | -$309.81M+27.1% | -$425.15M+14.6% | ||
| -27.7%+3.6pp | -31.3%+10.2pp | -41.5%+18.6pp | -60.1%+73.9pp | -134%+142pp | ||
| $26.83M+20.3% | $22.31M+27.4% | $17.51M+27.5% | $13.74M-2.8% | $14.13M-3.7% | ||
| $36.24M-3.0% | $37.36M-4.2% | $38.98M-6.5% | $41.7M-12.6% | $47.69M+2.2% | ||
| -$2.56M-452% | -$463K-38.2% | -$335K-698% | -$42K— | $0— | ||
| -$309.44M-7.3% | -$288.28M+0.3% | -$289.13M-2.6% | -$281.9M+28.0% | -$391.59M+15.9% | ||
| -27.3%+2.8pp | -30.1%+9.0pp | -39%+15.6pp | -54.7%+68.7pp | -123.4%+135pp | ||
| -$10.79-6.3% | -$10.15— | —— | —— | —— | ||
| -$10.79-6.3% | -$10.15— | —— | —— | —— | ||
| 114.2M+0.8% | 113.2M+1.3% | 111.7M+6.4% | 105M+7.0% | 98.1M+9.0% | ||
| 114.2M+0.8% | 113.2M+1.3% | 111.7M+6.4% | 105M+7.0% | 98.1M+9.0% | ||
| -$2.56M-452% | -$463K-38.2% | -$335K-698% | -$42K— | $0— | ||
| $453.05M+16.6% | $388.53M+30.4% | $297.91M+54.6% | $192.64M-8.1% | $209.65M-11.4% | ||
| $1.13B+18.2% | $958.4M+29.4% | $740.64M+43.7% | $515.55M+62.4% | $317.38M+76.2% | ||
| -$313.51M-4.5% | -$300.1M+2.4% | -$307.48M+0.8% | -$309.81M+27.1% | -$425.15M+14.6% | ||
| -$312M-4.5% | -$298.59M+2.4% | -$306.01M+0.8% | -$308.4M+27.2% | -$423.84M+14.7% | ||
| -$312M-4.5% | -$298.59M+2.4% | -$306.01M+0.8% | -$308.4M+27.2% | -$423.84M+14.7% | ||
| -27.5%+3.6pp | -31.2%+10.2pp | -41.3%+18.5pp | -59.8%+73.7pp | -133.5%+142pp | ||
| -$313.51M-4.5% | -$300.1M+2.4% | -$307.48M+0.8% | -$309.81M+27.1% | -$425.15M+14.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s revenue?
- Madrigal Pharmaceuticals, Inc. (MDGL) generated $1.1B in revenue over the trailing twelve months, up 256.8% year over year.
- Is Madrigal Pharmaceuticals, Inc. profitable?
- Madrigal Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $309.4M over the trailing twelve months, a -27.3% net margin.
- What are Madrigal Pharmaceuticals, Inc.'s profit margins?
- Gross margin is 96.5% and operating margin is -27.7%, with a -27.3% net margin.
- What is Madrigal Pharmaceuticals, Inc.'s earnings per share?
- Madrigal Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-10.79.
- Where does Madrigal Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Madrigal Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
